Tharimmune, Inc. will present at three Fall conferences, showcasing new results in inflammation and immunology research.
Quiver AI Summary
Tharimmune, Inc., a clinical-stage biotechnology company focused on innovative therapeutics for inflammation and immunology, announced its participation in three upcoming conferences this fall. The company will present new research at the American College of Gastroenterology Annual Scientific Meeting from October 24-29 in Phoenix, AZ, the American Association for the Study of Liver Diseases Annual Conference from November 7-10 in Washington, DC, and the AAPS PharmSci 360 from November 9-12 in San Antonio, TX. Tharimmune's lead clinical asset, TH104, targets conditions such as respiratory and nervous system depression related to opioid exposure and other indications like chronic pruritus. The company emphasizes its commitment to patient-centered innovation and long-term shareholder value.
Potential Positives
- Tharimmune is showcasing new research results at multiple prestigious medical conferences, which can enhance its visibility within the biotech and medical communities.
- The company's participation in these conferences may facilitate networking opportunities with key opinion leaders, potential partners, and investors.
- Tharimmune's lead clinical asset, TH104, addresses critical unmet medical needs, such as respiratory and/or nervous system depression related to opioid exposure, indicating potential for significant impact and market demand.
- The announcement reinforces Tharimmune’s commitment to innovation in immunology and inflammation, positioning the company favorably within a competitive sector.
Potential Negatives
- Press release highlights a reliance on forward-looking statements, indicating uncertainty about the company's plans and future performance.
- The acknowledgment of potential risks related to their projected objectives may raise concerns among investors regarding the company's stability and growth potential.
- Details about specific upcoming conference presentations could suggest that the company is still in the early stages of research and development, potentially indicating a lack of immediate market-ready products.
FAQ
What conferences will Tharimmune attend in Fall 2025?
Tharimmune will attend the ACG Annual Scientific Meeting, AASLD Annual Conference, and AAPS PharmSci 360 in Fall 2025.
When is the ACG Annual Scientific Meeting?
The ACG Annual Scientific Meeting will take place from October 24-29, 2025, with Tharimmune's presentation on October 26.
Where will the AASLD Annual Conference be held?
The AASLD Annual Conference will be held at the Washington Convention Center in Washington, DC from November 7-10, 2025.
What is Tharimmune's lead clinical asset?
Tharimmune's lead clinical asset is TH104, developed for respiratory and/or nervous system depression in specific high-risk scenarios.
How does Tharimmune contribute to biotechnology?
Tharimmune focuses on innovative therapies for inflammation, immunology, and oncology, aiming to meet critical medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating in three upcoming Fall conferences.
The Tharimmune team will present new results at the American College of Gastroenterology (ACG) Annual Scientific Meeting, being held October 24-29, 2025 at the Phoenix Convention Center in Phoenix, AZ; and the American Association for the Study of Liver Diseases (AASLD) Annual Conference, The Liver Meeting® 2025 to be held November 7 -10, 2025, in Washington, DC; as well as the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 to be held November 9-12, 2025, in San Antonio, Texas.
| Event: | ACG 2024 Annual Scientific Meeting |
| Date: | Sunday, October 26, 2025 |
| Time: | 3:30 p.m. – 4:30 p.m. Pacific Time |
| Location: |
Exhibit Hall, Phoenix Convention Center
|
| Event: | The Liver Meeting® 2025 Annual Scientific Meeting |
| Date: | Monday, November 10, 2025 |
| Time: | 1:00 p.m. – 2:00 p.m. Eastern Time |
| Location: |
Exhibit Hall, Washington Convention Center
|
| Event: | AAPS PharmSci 360 2025 Annual Scientific Meeting |
| Date: | November 9 - 12, 2025 |
| Session: | Late Breaker Poster Session Event |
| Location: | Henry B. Gonzalez Convention Center, San Antonio, TX |
About Tharimmune, Inc.
Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick ™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com .
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.
Contacts:
Tharimmune, Inc.
[email protected]
